SAM
BCYC

Silvercrest Asset Management’s Bicycle Therapeutics BCYC Stock Holding History

Silvercrest Asset Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.99M Sell
428,684
-48,292
-10% -$276K 0.01% 530
2025
Q4 		$3.38M Hold
476,976
– – 0.02% 477
2025
Q3 		$3.69M Buy
476,976
+211,283
+80% +$1.59M 0.02% 465
2025
Q2 		$1.85M Hold
265,693
– – 0.01% 564
2025
Q1 		$2.26M Buy
265,693
+127,953
+93% +$1.51M 0.02% 526
2024
Q4 		$1.93M Sell
137,740
-1,353
-1% -$29K 0.01% 535
2024
Q3 		$3.15M Buy
+139,093
New +$3.21M 0.02% 436

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Silvercrest Asset Management's BCYC Position: Q1 2026 in Review

Silvercrest Asset Management reduced its Bicycle Therapeutics (BCYC) stake by 10% in Q1 2026, selling an estimated $276K and leaving 428,684 shares worth $1.99M. The position accounts for 0.01% of the portfolio, ranked #530.

Silvercrest Asset Management first reported a position in BCYC in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.69M in Q3 2025. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Silvercrest Asset Management held 428,684 shares of Bicycle Therapeutics worth $1.99M as of Q1 2026.
  • Silvercrest Asset Management sold 48,292 Bicycle Therapeutics shares in Q1 2026, an estimated $276K.
  • Bicycle Therapeutics made up 0.01% of Silvercrest Asset Management's portfolio in Q1 2026, its #530 holding.
  • Silvercrest Asset Management first reported a position in Bicycle Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Silvercrest Asset Management's Bicycle Therapeutics position peaked at $3.69M in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.